We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Groups Seek Clarity on IRB, Sponsor Responsibilities in Trial Oversight Guidance
Groups Seek Clarity on IRB, Sponsor Responsibilities in Trial Oversight Guidance
January 29, 2013
Industry and patient advocacy groups are asking the FDA to clarify roles and terminologies in response to its recent draft guidance on oversight of investigators and sites and IND approvability.